Skip to Main Content

A new analysis of Vascepa, a medicine derived from fish oil and used to prevent heart attacks in a select group of patients, raises big questions about the evidence that the medicine is effective. Several experts say the questions require a new clinical trial to be conducted, and some even say the Food and Drug Administration should reconsider the product’s approval.

In a twist, the new data come from an analysis funded by Amarin itself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment